Breaking Down C.Q. Pharmaceutical Holding Co., Ltd. Financial Health: Key Insights for Investors

Curious whether C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) is a turnaround story or a balance-sheet risk waiting to happen? This deep-dive unpacks how Q3 2025 revenue of CNY 21.02 billion (up 5.57% YoY) and a trailing twelve months revenue of CNY 83.08 billion (TTM as of Sept 30, 2025; +4.23% YoY) coexist with a modest Q3 net income attributable to shareholders of CNY 101.74 million (an 87.94% YoY jump) and a low net profit margin of 0.48%, while the balance sheet shows total assets of CNY 67.71 billion against liabilities of CNY 51.24 billion and a leveraged structure marked by a debt-to-equity ratio of 1.39; liquidity and solvency metrics-cash & short-term investments down 20.77% to CNY 5.31 billion, an Altman Z-Score of 1.73, a Piotroski F-Score of 5, operating cash flow (TTM) of CNY 800.08 million and free cash flow of CNY 517.13 million-raise important flags as do valuation indicators such as a market capitalization of CNY 10.78 billion, trailing P/E of 29.78, P/S of 0.11 and P/B of 0.53; juxtapose these with segment-level drivers-pharmaceutical revenue of CNY 66.15 billion in 2024, traditional Chinese medicine and hemp extract sales of CNY 14.86 billion and CNY 3.02 billion, and a 6.4% rise in equipment revenue to CNY 12.75 billion-and the company's planned CNY 3 billion accounts-receivable securitization, broad 31-province distribution and push into IVD and high-margin equipment make the trade-offs between risk and growth especially nuanced-dig into the full analysis for detailed ratios, cash-flow breakdowns and scenario-driven implications.

C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) - Revenue Analysis

• Q3 2025 revenue: CNY 21.02 billion, +5.57% year-over-year (Q3 2024 comparison).
• TTM revenue as of Sep 30, 2025: CNY 83.08 billion, +4.23% YoY.
• Full-year 2024 revenue: CNY 80.56 billion, +2.76% vs. 2023.

• Pharmaceuticals remain the dominant revenue engine (CNY 66.15bn in 2024), representing the majority of total sales with modest mid-single-digit growth.
• Equipment segment shows stronger proportional growth (+6.4% in 2024), indicating investment-driven or aftermarket demand resilience.
• Traditional Chinese medicine (CNY 14.86bn) and hemp extract (CNY 3.02bn) are notable specialty-product contributors that diversify the revenue base.
• TTM growth (4.23%) and Q3 quarterly acceleration (+5.57%) suggest continued top-line momentum into late 2025.

C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) - Profitability Metrics

• Net income attributable to shareholders (Q3 2025): CNY 101.74 million, up 87.94% YoY versus Q3 2024.
• Net profit margin (Q3 2025): 0.48%, indicating margin recovery compared with the prior quarter.
• TTM net income as of Sept 30, 2025: CNY 374.78 million.
• Basic EPS (Q3 2025): CNY 0.06, up from CNY 0.03 in Q3 2024.
• Operating margin (Q3 2025): 1.51%, reflecting improved operational efficiency.
• EBITDA margin (Q3 2025): 1.81%, signaling stronger EBITDA generation relative to revenue.

• Year-over-year net income nearly doubled in Q3 2025, a strong signal of recovery or one-off favorable items boosting bottom-line results.
• Margins (net, operating, EBITDA) expanded, suggesting improving cost control or higher-margin revenue mix.
• EPS doubling to CNY 0.06 improves per-share return but remains modest in absolute terms - monitor sustainability across future quarters.
• TTM net income of CNY 374.78M provides a fuller-year lens showing cumulative earnings strength through September 2025.

C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) - Debt vs. Equity Structure

Key balance sheet and leverage metrics as of September 30, 2025 highlight a capital structure with significant indebtedness relative to equity and modest coverage of interest obligations.

• Total equity of CNY 16.47 billion (calculated) versus CNY 51.24 billion liabilities underscores leverage concentration in liabilities.
• A debt-to-equity ratio of 1.39 indicates more than one yuan of debt per yuan of equity - a levered balance sheet compared with conservative peers.
• Net debt to equity at 104.7% signals that net debt slightly exceeds equity, magnifying downside risk if earnings weaken.

• Interest coverage of 1.17 shows operating income covers interest only by a narrow margin, increasing vulnerability to rising rates or profit compression.
• Current ratio of 1.28 and quick ratio of 1.00 suggest adequate near-term liquidity, but limited cushion beyond immediate obligations.

For more context on shareholder base and investor activity related to these financials, see: Exploring C.Q. Pharmaceutical Holding Co., Ltd. Investor Profile: Who's Buying and Why?

C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) - Liquidity and Solvency

C.Q. Pharmaceutical's recent liquidity and solvency indicators show mixed signals: decent operational cash generation and large working capital, but declining short-term cash buffers and an Altman Z-Score that flags elevated bankruptcy risk.

• Cash & short-term investments (as of 30 Sep 2025): CNY 5.31 billion (down 20.77% year-on-year).
• Operating cash flow (TTM ending Mar 2025): CNY 800.08 million.
• Free cash flow (TTM ending Mar 2025): CNY 517.13 million - positive and indicates cash generation after capex.
• Working capital: CNY 12.82 billion, supporting short-term obligations and operations.
• Altman Z-Score: 1.73 - in the distress range, signaling increased bankruptcy risk compared with healthy peers.
• Piotroski F-Score: 5 - moderate financial strength (mixed operating/profitability signals).

• Implications for short-term liquidity: working capital is strong, but the 20.77% drop in cash and short-term investments reduces immediate liquidity cushions.
• Implications for solvency: positive free cash flow supports debt servicing, but Altman Z-Score (1.73) suggests balance-sheet vulnerability if adverse shocks occur.
• Operational view: operating cash flow of CNY 800.08 million confirms core cash generation; continued FCF is a constructive sign if sustained.

For broader investor context and ownership trends, see: Exploring C.Q. Pharmaceutical Holding Co., Ltd. Investor Profile: Who's Buying and Why?

C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) - Valuation Analysis

• P/E = 29.78 suggests investors pay nearly 30x trailing earnings; sensitivity to earnings volatility is higher.
• P/S = 0.11 and EV/S = 0.37 point to an inexpensive valuation on a top-line basis, possibly reflecting thin margins or market concerns.
• P/B = 0.53 indicates the stock trades at a discount to book value, which can signal undervaluation or asset-quality questions.
• EV/EBITDA = 18.12 implies the market values operating cash flows more richly than sales/book multiples do; reconciliation between these ratios is necessary.

• For value investors: low P/S and P/B may be attractive but require due diligence on revenue quality and balance-sheet risks.
• For growth/earnings-focused investors: the near-30x P/E and EV/EBITDA 18.12 demand confidence in earnings sustainability and margin expansion.
• Relative comparison: juxtapose these multiples with sector peers and historical ranges to assess whether the mixed signals reflect company-specific issues or broader sector dynamics.

C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) - Risk Factors

• Leverage risk: With a debt-to-equity of 1.39, the company carries significant financial obligations relative to shareholder capital, increasing refinancing and covenant breach risk if earnings decline.
• Interest burden: An interest coverage ratio of 1.17 implies only a 17% cushion of operating earnings above interest costs; a modest drop in EBIT could lead to inability to meet interest payments.
• Cash-generation shortfall: Operating cash flow at CNY -186.7 million indicates operations are not producing cash, forcing reliance on external financing, asset sales, or working-capital draws.
• Distress indicator: Altman Z-Score of 1.73 places the firm in the distress zone where default probability is materially higher than peers in healthy ranges (>2.99).
• Mixed fundamentals: A Piotroski F-Score of 5 shows neutral/mixed improvements - some quality signals exist but insufficient to offset leverage and cash concerns.
• Tiny margins: Net profit margin at 0.48% leaves little room to absorb cost inflation, price pressure, or one-time charges.

• Operational amplification: Negative operating cash flow combined with low margins may force cost cutting that could impair R&D, supply reliability, or regulatory compliance.
• Refinancing timeline: High leverage necessitates monitoring upcoming debt maturities; short-term maturities could create liquidity squeezes.
• Market sensitivity: Earnings or revenue volatility (e.g., product launches, pricing changes, reimbursement shifts) will disproportionately affect solvency metrics.

• Monitoring checklist for investors:
  • Quarterly operating cash flow trends and drivers of the CNY -186.7m shortfall
  • Changes in interest coverage and any refinancing terms or covenant waivers
  • Quarterly updates to Altman Z-Score components (working capital, retained earnings, EBIT)
  • Profitability initiatives and progress against lifting the 0.48% net margin
• Reference for strategic framing: Mission Statement, Vision, & Core Values (2026) of C.Q. Pharmaceutical Holding Co., Ltd.

C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) - Growth Opportunities

• Accounts receivable asset securitization plan: proposed issuance not exceeding CNY 3.0 billion to optimize leverage and shorten the cash-conversion cycle.
• Equipment segment momentum: reported 6.4% revenue growth in 2024, indicating scalable demand for manufacturing and high-hair equipment products.
• Geographic reach: distribution network covers all 31 provincial administrative regions in China, providing broad market access and cross-regional scaling potential.
• Portfolio expansion: strategic entry and development in traditional Chinese medicine (TCM) and hemp extract markets to diversify revenue and capture higher-margin specialty segments.
• Specialized investments: ramping investment into IVD (in vitro diagnostics) and other specialized segments to capture growth in precision healthcare.
• Industrial optimization: ongoing efforts to optimize industrial structure and lift operating income through cost discipline and higher-value product mix.

• Near-term liquidity and balance-sheet effects: the CNY 3 billion securitization, if executed, would convert receivables into cash, easing working-capital constraints and potentially enabling faster capex for IVD and equipment expansion.
• Revenue diversification: combining a national distribution footprint with new product verticals (TCM, hemp extract, IVD) reduces concentration risk tied to any single product line or geography.
• Scalability signals: 6.4% equipment revenue growth in 2024-coupled with targeted investment in high-hair equipment and diagnostics-suggests management is prioritizing segments with higher unit economics.